Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis

A Multicenter, Randomized, Double-blind, Parallel, Active-controlled, Superiority, Phase III Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis

A Multicenter, Randomized, Double-blind, Parallel, Active-controlled, Superiority, Phase III Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis

Inclusion Criteria:

• Male and female participants 19 years ≤ age ≤ 80 years
• Patients with acute bronchitis presenting with productive cough symptoms within 48 hours prior to Visit 2 (Baseline)
• BSS total score ≥ 5 at Visit 2, including Cough score ≥ 2, Sputum score ≥ 1
• Patients who voluntarily signed the consent form

Exclusion Criteria:

• Severe lung disease as determined by the investigator
• Clinically significant abnormal findings or signs on chest X-ray suggesting diagnoses other than acute bronchitis
• Active infection requiring systemic antibiotic treatment
• Patients who need to take contraindicated concomitant medications